Skip to content
PICO Portalanswers from OpenAlex

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea

PaperCitations, authors & open-access status

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea is a paper indexed in PICO Portal from OpenAlex.

How many citations does Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea have?

PICO Portalcitation count

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea has 33 citations in the OpenAlex counts PICO Portal stores.

When was Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea published?

PICO Portalyear

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea has 2015 year in the PICO Portal index.

What is the open-access status of Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea?

PICO Portaloa status

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea has bronze oa status in the PICO Portal index.

What is the DOI of Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea?

PICO Portaldoi

The DOI for Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea is on the source record.

What is the PMID of Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea?

PICO Portalpmid

The PMID for Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea is on the source record.

What is the OpenAlex record for Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea?

PICO Portalopenalex

The OpenAlex for Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial